ReviewTranslational andrology and urology2025
Modulators of urinary pH in the context of urinary stone disease: a literature review.
Review in Translational andrology and urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Urinary pH is an important factor in the preventative management of kidney stones. A variety of options are available for modulating urinary pH, including pharmaceuticals, over the counter (OTC) formulations [such as stone specific OTCs, complementary and alternative medicines (CAMs), and home remedies], and dietary modifications. These options can be overwhelming for both providers and patients and vary with regards to cost, convenience, and efficacy. In the absence of a consolidated central source of information for patients and physicians to reference, our study aims to summarize and analyze the effectiveness of these various treatment approaches to provide a more comprehensive understanding of how common interventions alter urinary pH. Methods: The PubMed database was used to identify human clinical trials related to pharmacologic and dietary interventions to modify urinary pH. Eligible studies were selected based on the following criteria: (I) observational or interventional study; (II) urinary pH as a reported outcome of the study intervention; (III) inclusion baseline or control urinary pH data; (IV) sufficient presentation of data for analytical purposes. Data was abstracted, and the mean changes in urinary pH for each intervention were compiled and grouped. Key Content and Findings: A total of 86 studies met inclusion criteria: 61 were randomized clinical trials, 20 were crossover or prospective studies, and 5 were observational cohort reports. In total, 150 individual experiments with a combined sample size of 2,895 were included. For urinary alkalinization, the most effective pharmaceutical, OTC formulation, and dietary change were sodium bicarbonate, Citro-Soda Conclusions: Our study found that pharmaceuticals are not the only effective options for altering urine pH; select dietary changes and OTC options are also viable for patients. When considering cost, accessibility and side effects, these alternative options may be more appealing to some patients, potentially improving adherence compared to pharmaceuticals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.